Nuvectis Pharma, Inc. terminated its prior at-the-market (ATM) offering program effective July 20, 2026, and entered into a new Open Market Sale Agreement with Jefferies LLC on August 21, 2026. Under the new agreement, the company may offer and sell shares of common stock from time to time through Jefferies acting as sales agent. The offering is part of a new shelf Registration Statement on Form S-3 filed on August 21, 2026, which registers up to $200 million in securities. Jefferies will receive compensation of up to 3.0% of the gross proceeds from any ATM shares sold. Nuvectis Pharma operates in the biotechnology industry and develops pharmaceutical products.
